Background. Dentists wrote 6.4% of all opioid prescriptions in the United States in 2012. The purpose of this study was to examine opioid prescription rates, dosage of opioids prescribed, type of opioid drug prescribed, and type of dental visit at which dentists prescribe opioids.
increased availability was associated with higher rates of opioid drug abuse. 8 Investigators in 1 study found that patients did not use 54% of the opioids prescribed during dental surgery. 9 Given the high prescription rates, the potential for drug misuse, and the severe ongoing opioid addiction epidemic, it is important to understand opioid prescription practices and trends in dentistry. The purpose of this study was to describe opioid prescription rates, dosage of opioids prescribed, type of opioid drug prescribed, and type of dental visit at which dentists more frequently prescribe opioids in a large sample of people who are privately insured in the United States.
METHODS

Data source
We used integrated dental, pharmacy, and medical claims from Truven Health Marketscan Research (Truven) databases. 10 These databases contain claims from people who are privately insured and are the largest convenience sample of the privately insured population. The data primarily are obtained from large employers. 11 The Truven databases are large enough to be nationally representative of the privately insured population. 10 We also used the Prescription Drug Monitoring Program (PDMP) Training and Technical Assistance Center (TTAC) conversion data set to calculate the daily MME dose. 12 For example, Percocet (Endo Pharmaceuticals) is a combination drug of acetaminophen and oxycodone. According to the MME conversion factor, 1 milligram of oxycodone is equivalent to 1.5 mg of morphine, so a Percocet tablet with 5 mg of oxycodone is equivalent to 7.5 mg of morphine or has a dose of 7.5 MME.
Study sample
We selected patients younger than 65 years who had at least 1 prescription of opioids and at least 1 dental claim from January 1, 2010, through December 31, 2015, and who were enrolled simultaneously in a medical and dental plan. eTable 1 13, 14 (available online at the end of this article) lists the opioid drugs we considered for this study and their MME conversion factors. We compiled the list of opioid drugs on the basis of the PDMP TTAC list 13 and the Centers for Medicare & Medicaid Services list.
14 Figures 1 and 2 outline the sample selection criteria. The sample population consisted of 1,558,446 opioid prescription claims from 1,135,344 patients.
Measures
We defined an opioid prescription as dental related if it occured within 3 days of a dental visit and there was no inpatient or outpatient claim within those same 3 days. We calculated the number of dental opioid prescriptions per 1,000 dental visits as the total number of dental opioid prescriptions divided by the total number of dental visits among patients enrolled in both a medical and dental plan, and then we multiplied it by 1,000. We further calculated the number of dental opioid prescriptions per 1,000 dental patients according to age group as the total number of dental opioid prescriptions in an age group divided by the total number of dental patients in that age group enrolled in both a medical and dental plan, and then we multiplied it by 1,000.
The Truven database reports the number of days of drug therapy covered by the prescription (days' supply), the number of units of drug dispensed (quantity), and the strength of the drug (strength). We obtained the MME dose by merging the Truven data sets with the PDMP TTAC conversion data set. We calculated the daily dose as the total strength of number of drug units per day (daily dose ¼ quantity Â strength / days' supply). We calculated the daily MME dose as the MME conversion factor multiplied by the daily dose. We calculated the average number of days' supply, quantity prescribed, and daily MME dose according to age group. We also identified the opioid drugs dentists most frequently prescribed. We used the sample population from Figure 1 to calculate the measures described.
We categorized each dental visit at which a dentist prescribed opioids as surgical, nonsurgical, presurgical, or postsurgical. We identified surgical procedures on the basis of the American Dental Association Current Dental Terminology codebook [15] [16] [17] [18] [19] and expert opinion from researchers at academic institutions. eTable 2 (available online at the end of this article) includes the list of all procedures that we considered surgical. If a dental visit had any of the procedure codes that we considered surgical services, we considered that dental visit as a surgical visit for this study. If a dental visit had none of the procedure codes that we considered surgical services, we considered that dental visit as a nonsurgical visit. It is possible that patients who received an opioid prescription during a nonsurgical dental visit received opioids because they had planned surgical treatment that was not initiated during that particular visit. The opioids may have been a way to manage pain until definitive surgical treatment could be started. To adjust for this possibility, we classified nonsurgical visits with opioid prescriptions that preceded a surgical visit within 15 days as presurgical visits. Similarly, a patient may have prolonged pain after a surgical visit. We adjusted for this possibility by categorizing those nonsurgical visits with opioid prescriptions that succeeded a surgical visit within 15 days as postsurgical visits. We used a subset of the sample population to categorize dental visits into these 4 distinct categories as Figure 2 shows. The subsample population in our study consists of 1,276,738 opioid prescription claims from 1,004,858 patients. JADA 149(4) n http://jada.ada.org n April 2018
We then calculated the rate of opioid prescriptions according to age group for surgical, presurgical, and nonsurgical dental visits. We also calculated the number of days' supply, quantity prescribed, and daily MME dose for surgical, presurgical, postsurgical, and nonsurgical dental visits. Furthermore, we calculated the rate of opioid prescriptions for each category of dental procedures (that is, restorative; endodontic; periodontic; prosthodontic: removable; maxillofacial prosthetics; implant services; prosthodontics: fixed; oral and maxillofacial surgery; orthodontic; and adjunctive general services) separately for both surgical and nonsurgical dental visits. We counted each procedure performed during a visit. For example, if the dentist performed an endodontic procedure and an adjunctive general service procedure during a nonsurgical dental visit associated with an opioid prescription, we counted both the endodontic and adjunctive general service procedures in their respective categories as procedures during a nonsurgical dental visit at which the dentist prescribed opioids. Each dental visit is likely to have a diagnostic or preventive procedure associated with it. Hence, we excluded the diagnostic and preventive procedures from the pool of procedures performed during surgical and nonsurgical dental visits.
Data analyses
We used statistical software (SAS 9.4, SAS Institute) for data analysis. We calculated descriptive statistics for days' supply, quantity prescribed, and daily MME dose. The data for days' supply, quantity prescribed, and daily MME dose were skewed, so we provided the median and interquartile range along with the mean and standard deviation.
RESULTS
In our sample of people who were privately insured, the number of opioid prescriptions written by dentists per 1,000 dental visits was 50.37 (95% confidence interval [CI], 50.17 to 50.58) in 2010, and it increased to 58.70 (95% CI, 58.48 to 58.92) in 2015. The number of opioid prescriptions written by dentists per 1,000 dental patients also increased from 130.58 (95% CI, 130.04 to 131.12) in 2010 to 147.44 (95% CI, 146.88 to 148.00) in 2015. There was a sharp increase in the number of opioid prescriptions per 1,000 dental patients for the group aged 11 through 18 years from 99.71 in 2010 to 165.94 in 2015. Table 1 presents the results for the number of opioid prescriptions per 1,000 dental patients according to age group.
The median number of days' supply of opioids dentists prescribed was 3 days for all age groups. The median quantity of opioids prescribed was highest (approximately 80) for the group younger than 11 years, but the median MME dose for patients younger than 11 years was only 10.80. The median quantity of opioids dentists prescribed was 20 for all age groups. The median daily MME dose dentists prescribed was 33.33 for all age groups; however, the median daily MME doses for groups aged 11 through 18 years and 19 through 25 years were 36.00 and 37.50, respectively. Table 2 summarizes the mean and median days' supply, quantity of opioids, and daily MME dose that dentists prescribed according to patient age group.
The 5 opioid drugs dentists most frequently prescribed were acetaminophen with hydrocodone bitartrate, acetaminophen with oxycodone hydrochloride, acetaminophen with codeine, hydrocodone bitartrate with ibuprofen, and tramadol hydrochloride. Acetaminophen with hydrocodone For all age groups, most dental visits at which dentists prescribed opioids were surgical dental visits (68.41%). The groups aged 11 through 18 years and 19 through 25 years had lower percentages of opioid prescriptions for nonsurgical dental visits than did the other age groups. Table 3 summarizes the percentages of opioid prescriptions according to age group and according to dental visit type (that is, surgical, presurgical, postsurgical, and nonsurgical dental visits).
For all age groups, the median days' supply dentists prescribed was 3 days for all 4 types of dental visits. The median quantity of opioids dentists prescribed was 18 for nonsurgical visits, 20 for surgical visits, 16 for presurgical visits, and 16 for postsurgical visits. The median daily MME dose dentists prescribed was 30.00 for nonsurgical visits, 33.33 for surgical dental visits, 37.50 for presurgical dental visits, and 33.33 for postsurgical dental visits.
After exclusion of diagnostic and preventive categories of procedures, restorative procedures constituted 55.57% of all procedures performed during a nonsurgical dental visit at which dentists prescribed opioids, and oral and maxillofacial surgery accounted for 59.11% of all procedures performed during a surgical dental visit at which dentists prescribed opioids. Table 4 summarizes the breakdown of dental procedures performed during nonsurgical and surgical dental visits at which dentists prescribed opioids.
DISCUSSION
The results of this study show that for people who were privately insured in the United States from 2010 through 2015, the rate of opioid prescriptions per 1,000 dental patients has increased, especially for the group aged 11 through 18 years. This age group also received a higher median daily MME dose compared to the median daily MME dose for all age groups, and approximately 89% of the opioids prescribed for this age group were associated with a surgical dental visit. Denisco and colleagues 21 estimated that 3.5 million people with an average age of 20 years may have been exposed to opioids through dentistry. Volkow and colleagues 5 reported that in 2009 dentists were the main prescribers of opioids for adolescents and young adults aged 10 through 19 years and prescribed 31% of all the opioid prescriptions for this age group. In a study of high school seniors, 36.9% of nonmedical users of prescription opioids used the drugs from their own previous prescriptions, and 27% of these prescriptions came from a dentist. 22 Results of our analysis help confirm the need for cautious opioid prescribing for this subpopulation to reduce the exposure and misuse of opioids at a younger age.
Our study results show that approximately 31% of the opioids prescribed for all age groups were associated with nonsurgical dental visits. This finding suggests there might be opportunities to reduce opioid prescription rates by targeting nonsurgical dental visit prescribing practices. Study results have shown that nonsteroidal anti-inflammatory drugs (NSAIDs) are effective for pain with few adverse effects, 23 whereas opioids are associated with more adverse effects. 24 Patients can manage pain by using optimal doses of NSAIDs at regular time intervals and by preoperative administration of NSAIDs in cases in which pain is anticipated. 25 Opioids can be considered if the pain persists after the optimal dose of NSAIDs has been reached. Investigators in 1 study noted that a combination of ibuprofen and acetaminophen can be more effective than opioids, with fewer adverse effects, in providing analgesia after third-molar extractions. 26 The National Academy of Medicine also recommends that dentists use nonopioid analgesics for pain management along with precautionary measures such as use of PDMPs, counseling patients about risks and benefits, and monitoring patients. 27 According to PDMP TTAC,
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PDMPs collect, monitor, and analyze electronically transmitted prescribing and dispensing data submitted by pharmacies and dispensing practitioners. The data are used to support states' efforts in education, research, enforcement and abuse prevention. PDMPs are managed under the auspices of a state, district, commonwealth, or territory of the United States.
PDMPs allow practitioners and pharmacists to obtain reports about opioid drug use for their patients, which they can use to prevent concurrent prescriptions and identify patients at risk of experiencing opioid drug abuse. However, investigators in 1 study reported that only 38% of dentists ever had accessed a PDMP. 29 Investigators in another study noted that mandatory use of a PDMP caused a 78% decrease in the quantity of opioids prescribed and an increase in the use of nonopioid analgesics. 30 Increased use of PDMPs among dentists and other health care providers can help identify patients at risk of experiencing opioid misuse or abuse, prevent concurrent prescriptions, and discourage drug shoppers.
In our sample, the use of hydrocodone decreased from 2014 through 2015, and the use of other drugs such as codeine and tramadol increased during the same time frame, which could be a possible effect of the reclassification of drugs. In October 2014, the US Drug Enforcement Administration reclassified hydrocodone as a schedule II drug from a schedule III drug. 31 Oxycodone is a schedule II drug, codeine is a schedule III drug, and tramadol is a schedule IV drug. 32 Schedule II drugs require a written prescription, whereas schedule III and IV drugs can be telephoned in to pharmacies. Because schedule II drugs are controlled more strongly and schedule III and IV drugs are easier and more convenient to prescribe, it is possible that the reclassification of hydrocodone helped reduce hydrocodone prescriptions while increasing the number of codeine and tramadol prescriptions; however, our study results do not establish causality. Nonetheless, hydrocodone still accounted for almost 63% of all opioid prescriptions written by dentists in 2015.
Limitations
There are several limitations to this study. This study is based on claims data for people who are privately insured. Hence, we cannot generalize the results of this study to the entire US population. However, given that the opioid addiction epidemic affects all income groups, 20 our sample may not 10 We excluded diagnostic and preventive procedures from this analysis. The sample population consists of 1,276,738 opioid prescription claims from 1,004,858 patients. † The percentages in this column are rounded and, hence, add up to 99.99%.
exhibit selection bias. The analysis is based on a large convenience sample of people who are privately insured but may not necessarily be nationally representative.
To obtain a prescriber source, we restricted our opioid claims data set to initial prescription fills only and did not account for refills. Usually, prescriptions from dentists are short term, designed to last a maximum of 5 days. Although it is possible that patients obtained refills, our data set does not account for those opioid claims. Therefore, our analyses could lead to underestimation of the rate of opioid use among dental patients.
In our study, we assumed that if a dentist prescribed an opioid, the level of pain was high enough to warrant filling that prescription within 3 days. It is possible that patients filled their prescriptions later than our assumption of 3 days and that we excluded these patients from our analyses. Because we did not have a definite prescriber source and had to rely on visit date and prescription fill date, our assumption best identified the prescriber while excluding other potential overlaps and refills. We acknowledge this as a limitation of our study.
CONCLUSIONS
Within a large population of people who were privately insured in the United States, the number of opioid prescriptions per 1,000 dental patients increased from 2010 to 2015, especially for the group aged 11 through 18 years. The number of days' supply prescribed was the same for all age groups. The quantity of opioids prescribed was 20. The groups aged 11 through 18 years and 19 through 25 years received higher daily MME doses than did the other age groups. Most opioids prescribed were associated with surgical dental visits. Although dentistry is accounting for less of the total volume of opioid prescriptions in the United States, results of our analysis suggest important areas of focus for further managing opioid prescribing among dentists. n SUPPLEMENTAL DATA Supplemental data related to this article can be found at: https://doi.org/10.1016/j.adaj.2018.01.005. 14 † The conversion factor in the table for buprenorphine and fentanyl is for tablet form. The conversion factor for buprenorphine transdermal patch (micrograms per hour) is 12.6 and buprenorphine film (micrograms) is 0.03. The conversion factor for fentanyl film or oral spray (micrograms) is 0.18, for fentanyl nasal spray (micrograms) is 0.16, and for fentanyl transdermal patch (micrograms per hour) is 7.2.
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CDT CODE DESCRIPTION D3429
Bone graft in conjunction with periradicular surgery e each additional contiguous tooth in the same surgical site
D3430
Retrograde filling -per root
D3431
Biologic materials to aid in soft and osseous tissue regeneration in conjunction with periradicular surgery
D3432
Guided tissue regeneration, resorbable barrier, per site, in conjunction with periradicular surgery
D3450
Root amputation -per root
D3460
Endodontic endosseous implant
D3470
Intentional reimplantation (including necessary splinting)
D3910
Surgical procedure for isolation of tooth with rubber dam D3920 Hemisection (including any root removal), not including root canal therapy
D4210
Gingivectomy or gingivoplasty -four or more contiguous teeth or tooth bounded spaces per quadrant
D4211
Gingivectomy or gingivoplasty -one to three contiguous teeth or tooth bounded spaces per quadrant
D4212
Gingivectomy or gingivoplasty to allow access for restorative procedure, per tooth
D4230
Anatomical crown exposure -four or more contiguous teeth or bounded tooth spaces per quadrant
D4231
Anatomical crown exposure -one to three teeth or bounded tooth spaces per quadrant
D4240
Gingival flap procedure, including root planing -four or more contiguous teeth or tooth bounded spaces per quadrant
D4241
Gingival flap procedure, including root planing -one to three contiguous teeth or tooth bounded spaces per quadrant
D4245
Apically positioned flap
D4249
Clinical crown lengthening e hard tissue
D4260
Osseous surgery (including elevation of a full thickness flap and closure) e four or more contiguous teeth or tooth bounded spaces per quadrant
D4261
Osseous surgery (including elevation of a full thickness flap and closure) e one to three contiguous teeth or tooth bounded spaces per quadrant
D4263
Bone replacement graft e retained natural tooth e first site in quadrant
D4264
Bone replacement graft e retained natural tooth e each additional site in quadrant
D4265
Biologic materials to aid in soft and osseous tissue regeneration 
D6101
Debridement of a peri-implant defect or defects surrounding a single implant, and surface cleaning of the exposed implant surfaces, including flap entry and closure
D6102
Debridement and osseous contouring of a peri-implant defect or defects surrounding a single implant and includes surface cleaning of the exposed implant surfaces, including flap entry and closure
D6103
Bone graft for repair of peri-implant defect e does not include flap entry and closure
D6104
Bone graft at time of implant placement D7111 Extraction, coronal remnants e primary tooth D7140 Extraction, erupted tooth or exposed root (elevation and/or forceps removal)
D7210
Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth, and including elevation of mucoperiosteal flap if indicated
D7220
Removal of impacted tooth -soft tissue
D7230
Removal of impacted tooth -partially bony
D7240
Removal of impacted tooth -completely bony
D7241
Removal of impacted tooth -completely bony, with unusual surgical complications
D7250
Removal of residual tooth roots (cutting procedure)
D7251
Coronectomy e intentional partial tooth removal
D7260
Oroantral fistula closure 
D7997
Appliance removal (not by dentist who placed appliance), includes removal of archbar
D7998
Intraoral placement of a fixation device not in conjunction with a fracture
D7999
Unspecified oral surgery procedure, by report
